pharmaceutical group governed by a foundation, announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in Stockholm. The Prix Galien...
We are delighted to invite you to the 2025 Asian Federation for Pharmaceutical Sciences (AFPS) Conference from 3 to 5 December 2025 in Sydney. We are delighted to invite you to the 2025 Asian Federation for Pharmaceutical Sciences (AFPS)...
was also approved by the European Commission (EC) and the U.S. Food and Drug Administration (FDA) in February and October 2025, respectively. About Eydenzelt® Eydenzelt® is a vascular endothelial growth factor (VEGF) inhibitor referencing Eylea®...
denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts....
LEQEMBI is currently approved in 51 countries and regions and is under regulatory review in 9 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance dosing after 18 months of IV treatment every two...
Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...
Asahi Kasei Corporation has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter, developed by its Asahi Kasei Bioprocess business unit. Designed...
its lead asset, HCB101, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland. Both datasets were accepted for late-breaking poster presentations, highlighting the...
of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, The new data demonstrate that VTAMA cream provided early and consistent response for children aged...
findings were presented at The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) 2025 in Washington, D.C. (November 7–11). Late-breaking, real-world data on Livdelzi, the only PBC treatment that provides...
mg formulation of chlorthalidone for the treatment of hypertension in adults. This milestone comes as the newly released 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults reemphasizes...
UCB will present six abstracts on BIMZELX in HS at the Symposium on Hidradenitis Suppurativa Advances (SHSA) 2025 congress in Nashville, Tennessee, October 31 to November 2, 2025. These data emphasize UCB's strength in providing rigorous,...
Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its...
was approved by the EC in November 2024 and by the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025 for the treatment of patients with Wet AMD, Visual Impairment due to Macular Oedema Secondary to RVO, Visual Impairment due...
At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg...
pharmaceutical and biotech industries from development to delivery. The 20,000-square-foot expansion, which began in Q4 2025 and is expected to be finalized in 2026, will significantly strengthen Alcami's analytical capabilities in support of...
and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 875 companies...
amyloid-beta (Aβ). Lecanemab has been approved in 50 countries and is under regulatory review in 8 countries. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was...
certification for compliance to the In Vitro Diagnostic Regulation (IVDR) in the European Union. “This week at ASHI 2025, we will highlight our continued investment in creating life changing solutions that allow transplant patients to thrive,” said...
disease, and kidney disease. Its lead asset, ENBUMYST™ (bumetanide nasal spray), was approved by the FDA on September 12, 2025 and is designed to offer rapid, reliable diuresis outside the hospital setting. About U.S. Heart and Vascular (USHV)...
